<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lin Z</submitter><funding>NCI NIH HHS</funding><pagination>1-20</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10927306</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8</volume><pubmed_abstract>Mesenchymal-epithelial plasticity driving cancer progression in cancer-associated fibroblasts (CAFs) is undetermined. This work identifies a subgroup of CAFs in human breast cancer exhibiting mesenchymal-to-epithelial transition (MET) or epithelial-like profile with high miR-200c expression. MiR-200c overexpression in fibroblasts is sufficient to drive breast cancer aggressiveness. Oxidative stress in the tumor microenvironment induces miR-200c by DNA demethylation. Proteomics, RNA-seq and functional analyses reveal that miR-200c is a novel positive regulator of NFκB-HIF signaling via COMMD1 downregulation and stimulates pro-tumorigenic inflammation and glycolysis. Reprogramming fibroblasts toward MET via miR-200c reduces stemness and induces a senescent phenotype. This pro-tumorigenic profile in CAFs fosters carcinoma cell resistance to apoptosis, proliferation and immunosuppression, leading to primary tumor growth, metastases, and resistance to immuno-chemotherapy. Conversely, miR-200c inhibition in fibroblasts restrains tumor growth with abated oxidative stress and an anti-tumorigenic immune environment. This work determines the mechanisms by which MET in CAFs via miR-200c transcriptional enrichment with DNA demethylation triggered by oxidative stress promotes cancer progression. CAFs undergoing MET trans-differentiation and senescence coordinate heterotypic signaling that may be targeted as an anti-cancer strategy.</pubmed_abstract><journal>Cell stress</journal><pubmed_title>MiR-200c reprograms fibroblasts to recapitulate the phenotype of CAFs in breast cancer progression.</pubmed_title><pmcid>PMC10927306</pmcid><funding_grant_id>P30 CA056036</funding_grant_id><funding_grant_id>R37 CA234239</funding_grant_id><funding_grant_id>K08 CA175193</funding_grant_id><pubmed_authors>Whitaker-Menezes D</pubmed_authors><pubmed_authors>Curry JM</pubmed_authors><pubmed_authors>Domingo-Vidal M</pubmed_authors><pubmed_authors>Caro J</pubmed_authors><pubmed_authors>Lin Z</pubmed_authors><pubmed_authors>Tuluc M</pubmed_authors><pubmed_authors>Roche ME</pubmed_authors><pubmed_authors>Diaz-Barros V</pubmed_authors><pubmed_authors>Uppal G</pubmed_authors><pubmed_authors>Martinez-Outschoorn U</pubmed_authors></additional><is_claimable>false</is_claimable><name>MiR-200c reprograms fibroblasts to recapitulate the phenotype of CAFs in breast cancer progression.</name><description>Mesenchymal-epithelial plasticity driving cancer progression in cancer-associated fibroblasts (CAFs) is undetermined. This work identifies a subgroup of CAFs in human breast cancer exhibiting mesenchymal-to-epithelial transition (MET) or epithelial-like profile with high miR-200c expression. MiR-200c overexpression in fibroblasts is sufficient to drive breast cancer aggressiveness. Oxidative stress in the tumor microenvironment induces miR-200c by DNA demethylation. Proteomics, RNA-seq and functional analyses reveal that miR-200c is a novel positive regulator of NFκB-HIF signaling via COMMD1 downregulation and stimulates pro-tumorigenic inflammation and glycolysis. Reprogramming fibroblasts toward MET via miR-200c reduces stemness and induces a senescent phenotype. This pro-tumorigenic profile in CAFs fosters carcinoma cell resistance to apoptosis, proliferation and immunosuppression, leading to primary tumor growth, metastases, and resistance to immuno-chemotherapy. Conversely, miR-200c inhibition in fibroblasts restrains tumor growth with abated oxidative stress and an anti-tumorigenic immune environment. This work determines the mechanisms by which MET in CAFs via miR-200c transcriptional enrichment with DNA demethylation triggered by oxidative stress promotes cancer progression. CAFs undergoing MET trans-differentiation and senescence coordinate heterotypic signaling that may be targeted as an anti-cancer strategy.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-06-23T03:17:58.983Z</modification><creation>2026-06-23T03:09:52.315Z</creation></dates><accession>S-EPMC10927306</accession><cross_references><pubmed>38476765</pubmed><doi>10.15698/cst2024.03.293</doi></cross_references></HashMap>